Strides Pharma Science Ltd announced its consolidated financial results for the quarter ended June 30, 2025 (Q1FY26). The company reported revenue of Rs. 1,119.7 crore.  reflecting a 6.2% year-on-year growth. Gross margin stood at Rs. 675.5 crore, increased by 11.7% year-on-year, with the gross margin percentage improving to 60.3%, up by 300 basis points compared to the same period last year.

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase, and EBITDA margin improved to 19.5%, representing a 150 basis point rise. Operational PAT was Rs. 114 crore, up by 80.6% compared to Q1FY25. The company also reported an operational earnings per share (EPS) of Rs. 12.4. Reported PAT for the quarter stood at Rs. 106.5 crore.

Strides’ U.S. business generated $71 million in revenue during the quarter, marking a 7% year-on-year growth.

Commenting on result, Badree Komandur, CEO, Strides Pharma Science, said: “We are pleased to report a solid start to the year, marked by consistent growth and enhanced profitability. Our focus on cost management and diligent execution has enabled us to deliver robust results. The EBITDA margin improved to 19.5%, an increase of 150bps YoY. Strong operating leverage contributed to the highest-ever quarterly PAT, resulting in an operational EPS of Rs. 12.4. Consequently, ROCE stands at 15.1% for Q1. The company will enhance its R&D efforts during the year to drive sustainable long-term growth.”